A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination With Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2022.
All research outputs
#8,796,056
of 26,169,168 outputs
Outputs from Frontiers in oncology
#3,444
of 22,913 outputs
Outputs of similar age
#166,484
of 451,275 outputs
Outputs of similar age from Frontiers in oncology
#206
of 1,549 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,275 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 1,549 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.
